Translational Research
Rarecells targets the development of three tests for early cancer diagnosis and is conducting three clinical studies
ISET Assay for Prostate Cancer Detection
In a collaboration with prestigious centers in France (Hôpital Foche and Hôpital Cochin), Rarecells is evaluating the performance of its dedicated ISET-based assay to allow accurate detection of prostate cancer and eliminate the need for unnecessary biopsies.
Size of cohort: 117 patients
ISET Assay for early detection of Myelodysplastic Syndrome and AML
In collaboration with Columbia University Irving Medical Center, Rarecells is investigating its dedicated assay to accurately monitor and detect at a very early stage blood disorders potentially leading to Acute Myeloid Leukemia.
Size of cohort: 300 patients
Follow up study of patients at increased risk of developing cancer
In collaboration with Columbia University’s First Cell Center for Cancer Surivors (FiCCCS), Rarecells will test blood samples of cancer survivors. This population is at higher risk of developing cancer. In fact, when adjusted for age and sex, the probability of a second new cancer among cancer survivors is twice as high as that in an individual who was never diagnosed with cancer. The collaboration will support the creation and management of a new biorepository of patients’ samples and enable next-generation sequencing analyses of ctDNA and ctcDNA in cancer survivors as a way to validate a multi-cancer non- invasive early diagnosis test.
Size of cohort: 48,000 patients